DashboardPortfoliosWatchlistCommunityDiscoverScreener
  • Community
  • /
  • Germany
  • /
  • Materials
Author Program NEWCreate Narrative
ACT logo

AlzChem Group AG Stock Price

XTRA:ACT Community·€1.7b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 62 Fair Values set on narratives written by author
Author Program NEWCreate Narrative

ACT Share Price Performance

€0
-141.40 (-100.00%)
​
€204.49
Fair Value
€0
-141.40 (-100.00%)
​
Price €0
Tue, 7 Jul 26
Fair Value€204.49
Share Pricen/a

ACT Community Narratives

AN
AnalystConsensusTarget
AnalystConsensusTarget's
Fair Value
·
Fair Value €204.49 21.6% undervalued intrinsic discount

ACT: Profitability Improvements And Product Launch Partnerships Will Support Fair Valuation

3users have liked this narrative
0users have commented on this narrative
25users have followed this narrative
AN
AnalystHighTarget
AnalystHighTarget's
Fair Value
·
Fair Value €253.97 36.8% undervalued intrinsic discount

Rising Global Protein Demand Will Fuel Sustainable Specialty Chemicals

0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
AN
AnalystLowTarget
AnalystLowTarget's
Fair Value
·
Fair Value €177 9.4% undervalued intrinsic discount

Rising Environmental Mandates And Input Costs Will Squeeze Margins

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
ACT logo
AlzChem Group
36.8% undervalued intrinsic discount

Rising Global Protein Demand Will Fuel Sustainable Specialty Chemicals

View narrative
AN
AnalystHighTarget
AnalystHighTarget
Updated 21 Jul
Read Narrative
ACT logo
AlzChem Group
21.6% undervalued intrinsic discount

ACT: Profitability Improvements And Product Launch Partnerships Will Support Fair Valuation

View narrative
AN
AnalystConsensusTarget
AnalystConsensusTarget
Updated 7 Jul
Read Narrative
ACT logo
AlzChem Group
9.4% undervalued intrinsic discount

Rising Environmental Mandates And Input Costs Will Squeeze Margins

View narrative
AN
AnalystLowTarget
AnalystLowTarget
Updated 23 Jun
Read Narrative

Trending Discussion

No trending discussion available.

Recently Updated Narratives

AN
AnalystHighTarget
ACT logo

ACT: Integrated Calcium Chain And US Expansion Will Support Future Cash Flows

Fair Value: €253.97 36.8% undervalued intrinsic discount
4 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystConsensusTarget
ACT logo

ACT: Niche Calcium Chain Platform And Dividend Policy Will Shape 2026 Outlook

Fair Value: €204.49 21.6% undervalued intrinsic discount
25 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystLowTarget
ACT logo

ACT: Specialty Platform And Value Chain Position Will Shape Cash Flow And Dividend

Fair Value: €177 9.4% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative

Snowflake Analysis

Flawless balance sheet and undervalued.

1 Risk
4 Rewards
View Full Analysis

AlzChem Group AG Key Details

€593.8m

Revenue

€204.1m

Cost of Revenue

€389.7m

Gross Profit

€321.9m

Other Expenses

€67.8m

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
Oct 29, 2026
6.69
65.63%
11.41%
32.4%
View Full Analysis

About ACT

Founded
1908
Employees
1680
CEO
Andreas Niedermaier
WebsiteView website
www.alzchem.com

AlzChem Group AG, together with its subsidiaries, develops, produces, and markets a range of chemical specialties in Germany, European Union, rest of Europe, Asia, NAFTA region, and internationally. It operates through three segments: Specialty Chemicals, Basics & Intermediates, and Other & Holding. The Specialty Chemicals segment sells specialty chemical products that are used in the chemical, food, animal feed, defence technology, and renewable energies industries. This segment manufactures composite materials and adhesives, as well as silicon nitride for ceramics; and photovoltaic modules in the solar industry. The Basics & Intermediates segment produces raw materials for specialty chemicals; and products for agriculture and metallurgy, as well as intermediates for the chemical industry that are produced from lime, carbon, and electricity. This segment also engages in the production and sale of guanidine salts as a raw material for agrochemicals and active pharmaceutical ingredients. The Other & Holding segment provides chemical park operations and administrative services, as well as produces and distributes various infrastructure services. It offers products and services to agricultural sector under the CALCIUM CYANAMIDE PERLKA, EMINEX, DORMEX, ALZOGUR, SITOFEX, and BREAK-THRU brands; animal nutrition sector under the CREAMINO brands; human nutrition sector under the CREAPURE, CREAVITALIS, LIVADUR, and ALIPURE brands; pharma sector under the GUANIDINE SALTS – BIOSELECT brand; fine chemicals sector under the GUANIDINSALZE -BIOSELECT, CYANAMIDE, DICYANDIAMIDE, GUANAMINE, NITRILES, MELFLOCK and ALZOFIX, THIOUREA, and NITROGUANIDINE brands; metallurgy sector under the CAD, CALCIPRO, and CALZOT brands, as well as technical gases and calcium carbide; renewable energy sector under the DYHARD and SILZOT brands; and custom synthesis, such as toll micronization and manufacturing. AlzChem Group AG was founded in 1908 and is based in Trostberg, Germany.

Recent ACT News & Updates

User avatar
Narrative Update • Jul 21

ACT: Integrated Calcium Chain And US Expansion Will Support Future Cash Flows

Analysts have raised their fair value estimate for AlzChem Group to about €254 from €200, citing recent research that highlights the company’s unique position in the calcium carbide and calcium cyanide value chain, along with updated assumptions for revenue growth, profit margins, and future P/E levels. Analyst Commentary Bullish analysts covering AlzChem Group highlight the company’s role in the calcium carbide and calcium cyanide value chain as a key support for current fair value assumptions and recent target price work.

Recent updates

No updates

AlzChem Group AG Competitors

EVK logo

Evonik Industries

Symbol: XTRA:EVK
Market cap: €8.4b
NDA logo

Aurubis

Symbol: XTRA:NDA
Market cap: €7.5b
WCH logo

Wacker Chemie

Symbol: XTRA:WCH
Market cap: €4.5b
SDF logo

K+S

Symbol: XTRA:SDF
Market cap: €3.1b
View more competitors

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide